^
Association details:
| Biomarker: | NTRK3 fusion |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
New sarcoma drug approved for use in England
Published date:
04/21/2020
Excerpt:
We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
Source:
Excerpt:
Uterine Sarcoma: Useful In Certain Circumstances…Larotrectinib or entrectinib for NTRK gene fusion-positive tumors...
Source:
Title:
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Excerpt:
...Patients must have a histologic diagnosis of infantile fibrosarcoma with an NTRK1, NTRK2, or NTRK3 fusion identified in a Clinical Laboratory Improvement Act/College of American Pathologists (CLIA/CAP) certified laboratory....
Trial ID:
Source:
Title:
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Excerpt:
...- Locally-advanced or metastatic malignancy with an NTRK1, NTRK2, or NTRK3 gene fusion, identified through molecular assays as routinely performed at CLIA or other similarly-certified laboratories....
Trial ID:
Less C2 evidence
Source:
Title:
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Published date:
09/28/2023
Excerpt:
Larotrectinib demonstrated robust and durable responses, extended survival benefit, and a favorable safety profile in adult patients with TRK fusion sarcomas with longer follow-up.
DOI:
https://doi.org/10.1002/cncr.35036
Trial ID:
Source:
Title:
Undifferentiated and Unresectable Sarcoma With NTRK3-Fusion in a Pediatric Patient Treated With Larotrectinib and Proton Beam Radiotherapy
Published date:
12/23/2021
Excerpt:
A 6-year-old female presenting with an abdominal mass was found to have an unresectable undifferentiated sarcoma...molecular testing identified an NTRK3-fusion, and treatment was changed to larotrectinib monotherapy....This drug was administered at a dose of 100 mg/m2 twice a day. A CT scan performed after 3 months of therapy demonstrated a very good partial response with a 95% decrease in tumor size, based on RECIST 1.1 criteria....The patient was maintained on larotrectinib, and 3 months after completing radiotherapy a repeat CT scan showed further minor reduction in the size of the tumor.... Larotrectinib was continued for 12 months following completion of radiotherapy, for a total of 22 months. The patient remains in remission 9 months after stopping all anticancer treatment.
